$1,509.60 general Payment -- Boehringer Ingelheim to Dr. Lisa Garcia

Cardiologist Dr. Lisa Garcia Receives $1509.60 Payment from Boehringer Ingelheim for Services

This page provides a detailed analysis of a $1,509.60 general payment from Boehringer Ingelheim to Dr. Lisa Garcia. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

FieldValue
Amount$1,509.60
Payment Typegeneral
Payment NatureCompensation for services other than consulting
Pharmaceutical CompanyBoehringer Ingelheim
PhysicianDr. Lisa Garcia
NPI Number1698950687
Physician SpecialtyCardiology
LocationSyracuse, NY
Date of Payment2024-11-26
Related Drug/DeviceRevlimid
Conflict AssessmentLow -- Routine

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Boehringer Ingelheim made a $1.5K general payment to Lisa Garcia, a Cardiology specialist in Syracuse, NY. The payment was associated with Revlimid. Boehringer Ingelheim made a payment of $1509.60 to Dr. Lisa Garcia, a cardiologist. The payment was for services other than consulting, specifically compensation for services. The payment was made on November 26, 2024, for Revlimid.

Patient Guidance: What This Payment Means for You

This payment to your physician is for services rendered and is publicly reported. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Payments to cardiologists for services other than consulting are common in the industry.

Regulatory Context: Sunshine Act Requirements

This payment is reported under the Physician Payments Sunshine Act, part of the Affordable Care Act.

Related Topics

This payment is related to the following healthcare transparency topics:

Understanding general Payments

general payments are one of several categories of financial transfers from pharmaceutical and medical device companies to physicians that must be reported under the Sunshine Act. Understanding the type and context of a payment is important for evaluating its significance. Not all payments are equal -- a research grant has very different implications than a promotional speaking fee.

Frequently Asked Questions About This Payment

What was this $1.5K payment for?

This was a general payment of $1.5K from Boehringer Ingelheim to Lisa Garcia, categorized as "Compensation for services other than consulting". It was associated with Revlimid. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Lisa Garcia accept pharmaceutical money?

Yes, Lisa Garcia received this $1.5K payment from Boehringer Ingelheim. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Lisa Garcia's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this general payment?

A general payment of $1.5K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Cardiology?

To compare this payment against Cardiology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Cardiology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Lisa Garcia's relationship with Boehringer Ingelheim?

The payment amount is $1509.60. This $1.5K general payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Cardiology?

The payment type is 'general'.

What should patients do after learning about this payment?

This payment to your physician is for services rendered and is publicly reported.

What else should I know about this general payment?

The payment nature is 'Compensation for services other than consulting'.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.